Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heather Franke

Internal Medicine Warren, MI Doctor of Osteopathy

NPI 1861710154 CMS profile 129480

11885 E 12 Mile Rd Ste 300A, Warren, MI 48093

Open in the dashboard

General payments

$5,202

122 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Franke of Warren, MI is reported in the CMS Open Payments database as having received $5,202 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,003 34
2024 General $1,973 31
2023 General $378 11
2022 General $798 14
2021 General $146 3
2020 General $369 8
2019 General $535 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Franke
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Heather Franke were reported at $1,003. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Heather Franke Internal Medicine median Middle half National median
2019 $535 $159 $48–$570 $163
2020 $369 $119 $33–$402 $114
2021 $146 $135 $37–$521 $132
2022 $798 $141 $42–$496 $149
2023 $378 $149 $45–$519 $160
2024 $1,973 $154 $47–$537 $164
2025 $1,003 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,433 9 payments
  2. Amgen Inc. $860 17 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $784 37 payments
  4. Edwards Lifesciences Corporation $518 13 payments
  5. Medtronic, Inc. $425 5 payments
  6. Boston Scientific Corporation $393 9 payments
  7. Shockwave Medical, Inc $172 1 payment
  8. E.R. Squibb & Sons, L.L.C. $116 7 payments
  9. Kestra Medical Technology Services, Inc. $113 4 payments
  10. Chiesi USA, Inc. $83 4 payments
  11. Other $306 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,218 116 payments
  2. Travel and Lodging $952 4 payments
  3. Education $33 2 payments
Products named General payments · program years 2019–2025
  1. MITRACLIP $1,017 6 payments
  2. LifeVest $784 37 payments
  3. Repatha $746 14 payments
  4. SAPIEN 3 Ultra RESILIA $518 13 payments
  5. COREVALVE EVOLUT R $379 3 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $172 1 payment
  7. CardioMEMS HF System $155 1 payment
  8. WATCHMAN FLX $137 4 payments
  9. EkoSonic $118 1 payment
  10. HeartMate 3 Left Ventricular Dev $103 1 payment
  11. Other $974 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,813

Median for Cardiology: 2,533

Drug cost

$414,558

Median for Cardiology: $485,213

Branded share of claims

28.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 164 $221,509
Xarelto Rivaroxaban Brand 39 $55,536
Entresto Sacubitril/Valsartan Brand 28 $46,520
Jardiance Empagliflozin Brand 23 $24,597
Praluent Pen Alirocumab Brand 31 $21,219
Repatha Sureclick Evolocumab Brand 26 $17,213
Isosorbide Dinitrate Generic 14 $4,013
Metoprolol Succinate Generic 188 $3,276
Atorvastatin Calcium Generic 149 $2,056
Losartan Potassium Generic 134 $1,748

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$132,992

Of which drugs: $806

Medicare patients

1,228

Average age 75

Services billed

2,423

644 women, 584 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Arthritis 59%
Heart failure 55%
Atrial fibrillation 48%
Chronic kidney disease 48%
Diabetes 47%
COPD 39%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, perflutren lipid microspheres, per ml Q9957 Office 18 18 $584
Injection, regadenoson, 0.1 mg J2785 Office 18 72 $223

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $35
$35 — —
KENGREAL
  • CHIESI USA, INC. $32
$32 — —
Repatha
  • Amgen Inc. $26
$26 26 —
Wegovy
  • Novo Nordisk Inc $25
$25 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $21
$21 39 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record